Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $43
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $43
Needham維持對Pacira BioSciences的買入，將目標股價下調至43美元
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $45 to $43.
Needham分析師塞爾吉·貝蘭格維持Pacira BioSciences（納斯達克股票代碼：PCRX）的買入並將目標股價從45美元下調至43美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。